EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC 4.0

Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial

Filip K Knop iD, George Kunos iD, Dror Dicker iD, Jean-Sebastien Paquette iD, Louis Aronne iD, Oscar Birkhan iD, Ofir Frenkel iD, Thomas Holst-Hansen iD, Karine Lalonde iD, Glenn Crater iD, trial investigators

Diabetes, Obesity and Metabolism · 2026-05 · 28 (5) · 4366-4371

DOI: 10.1111/dom.70580 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 24.03.2026. Verfasst von Filip K Knop und 10 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk, Søborg, Denmark. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Inversago Pharma Inc. (a Novo Nordisk company).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

antiobesity drugappetite controlclinical trialinsulin resistanceobesity therapyphase I‐II studyweight management

Autor:innen und Institutionen

  • Novo Nordisk, Søborg, Denmark.
  • Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, Bethesda, Maryland, USA.
  • Internal Medicine Department D and Obesity Clinic, Hasharon Hospital-Rabin Medical Center, Petach-Tikva, Gray Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Laboratoire de recherche et d'innovation en médecine de première ligne (ARIMED), Groupe de médecine de famille universitaire de Saint-Charles-Borromée, CISSS Lanaudière, Saint-Charles-Borromée, Québec, Canada.
  • VITAM Research Centre for Sustainable Health, Québec City, Québec, Canada.
  • Department of Family Medicine and Emergency Medicine, Faculty of Medicine, Université Laval, Québec City, Québec, Canada.

ORCID-Profile: Filip K Knop, George Kunos, Dror Dicker, Jean-Sebastien Paquette, Louis Aronne, Oscar Birkhan, Ofir Frenkel, Thomas Holst-Hansen, Karine Lalonde, Glenn Crater

Förderung

  • Inversago Pharma Inc. (a Novo Nordisk company)

Zitieren

APA

Knop, F. K., Kunos, G., Dicker, D., Paquette, J. S., Aronne, L., Birkhan, O., Frenkel, O., Holst-Hansen, T., Lalonde, K., Crater, G., & trial investigators (2026). Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial. Diabetes, Obesity and Metabolism, 28(5), 4366-4371. https://doi.org/10.1111/dom.70580

Vancouver

Knop FK, Kunos G, Dicker D, Paquette JS, Aronne L, Birkhan O, et al. Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial. Diabetes, Obesity and Metabolism. 2026;28(5):4366-4371. doi:10.1111/dom.70580

BibTeX
@article{Knop2026,
  author = {Knop, Filip K and Kunos, George and Dicker, Dror and Paquette, Jean-Sebastien and Aronne, Louis and Birkhan, Oscar and Frenkel, Ofir and Holst-Hansen, Thomas and Lalonde, Karine and Crater, Glenn and trial investigators, trial investigators},
  title = {Monlunabant in adults with obesity and metabolic syndrome: Open‐label extension of a phase 2a trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {5},
  pages = {4366--4371},
  doi = {10.1111/dom.70580}
}
Kostenlos starten →